US EditionAlcyone Therapeutics Announces Strategic Financing to Advance an Expanded Pipeline of Pediatric-Focused Precision Therapeutics for Severe Neurological Diseases
Summary by The Huntsville Item
2 Articles
2 Articles
All
Left
1
Center
Right
The Huntsville ItemReposted by 
chicagostarmedia.com
chicagostarmedia.comAlcyone Therapeutics Announces Strategic Financing to Advance an Expanded Pipeline of Pediatric-Focused Precision Therapeutics for Severe Neurological Diseases
Expanded collaboration with Nationwide Children's Hospital adds new funding and a third therapeutic candidate (CLN-301) to Alcyone's diversified portfolio of precision CNS therapeutics and delivery technologiesCLN-301 is a clinical-stage transformative gene therapy in development for CLN3 Batten disease (Juvenile Neuronal…
Coverage Details
Total News Sources2
Leaning Left1Leaning Right0Center0Last UpdatedBias Distribution100% Left
Bias Distribution
- 100% of the sources lean Left
100% Left
L 100%
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
